SAN

79.37

+1.59%↑

SRT3

214.5

+2.05%↑

ORNBV.FI

68.4

+3.79%↑

SAN

79.37

+1.59%↑

SRT3

214.5

+2.05%↑

ORNBV.FI

68.4

+3.79%↑

SAN

79.37

+1.59%↑

SRT3

214.5

+2.05%↑

ORNBV.FI

68.4

+3.79%↑

SAN

79.37

+1.59%↑

SRT3

214.5

+2.05%↑

ORNBV.FI

68.4

+3.79%↑

SAN

79.37

+1.59%↑

SRT3

214.5

+2.05%↑

ORNBV.FI

68.4

+3.79%↑

Search

Laboratorios Farmaceuticos Rovi SA

Abrir

SetorSaúde

79.55 1.99

Visão Geral

Variação de preço das ações

24h

Atual

Mín

77.8

Máximo

79.65

Indicadores-chave

By Trading Economics

Rendimento

-33M

43M

Vendas

7.9M

218M

P/E

Médio do Setor

33.602

67.147

EPS

0.834

Margem de lucro

19.539

Funcionários

1,950

EBITDA

-21M

63M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+8.85% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

79M

4.1B

Abertura anterior

77.56

Fecho anterior

79.55

Sentimento de Notícias

By Acuity

50%

50%

201 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de abr. de 2026, 23:53 UTC

Ganhos

Naver Posts Weaker First-Quarter Earnings

29 de abr. de 2026, 23:41 UTC

Ações em Alta

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 de abr. de 2026, 23:55 UTC

Ganhos

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 de abr. de 2026, 23:54 UTC

Ganhos

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 de abr. de 2026, 23:52 UTC

Ganhos

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 de abr. de 2026, 23:51 UTC

Ganhos

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 de abr. de 2026, 23:51 UTC

Conversa de Mercado

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 de abr. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 de abr. de 2026, 23:22 UTC

Ganhos

China Longyuan 1Q Net CNY1.70B, Down 14%

29 de abr. de 2026, 23:22 UTC

Ganhos

China Longyuan: Power Generation Down 2.9% as of End-March

29 de abr. de 2026, 23:20 UTC

Ganhos

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 de abr. de 2026, 23:20 UTC

Ganhos

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Loss Narrows>000002.SZ

29 de abr. de 2026, 23:18 UTC

Ganhos

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 de abr. de 2026, 23:17 UTC

Ganhos

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 de abr. de 2026, 23:15 UTC

Ganhos

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 de abr. de 2026, 23:15 UTC

Ganhos

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 de abr. de 2026, 23:13 UTC

Ganhos

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 de abr. de 2026, 23:12 UTC

Ganhos

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 de abr. de 2026, 23:11 UTC

Ganhos

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 de abr. de 2026, 23:11 UTC

Ganhos

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 de abr. de 2026, 23:04 UTC

Ganhos

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 de abr. de 2026, 23:04 UTC

Ganhos

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

8.85% parte superior

Previsão para 12 meses

Média 86.75 EUR  8.85%

Máximo 90 EUR

Mínimo 83.5 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

201 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat